Core Viewpoint - The collaboration between Sanofi and Pfizer for the dual-specific antibody SSGJ-707 marks a significant step in the global commercialization of innovative cancer therapies, enhancing the international recognition and accessibility of Sanofi's products [1][2]. Company Summary - Sanofi and its affiliates granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the dual-specific antibody SSGJ-707, with Pfizer retaining rights for commercialization in mainland China through additional payments [1]. - Pfizer will pay an upfront non-refundable fee of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales share based on product sales in authorized regions [1]. - The antibody SSGJ-707 targets PD-1 and VEGF, having received breakthrough therapy designation from the National Medical Products Administration for treating advanced non-small cell lung cancer (NSCLC) [1][2]. Industry Summary - The collaboration signifies recognition of Sanofi's dual-specific antibody research platform by a leading international company, which is expected to enhance the global reach and acceptance of its products [2]. - The SSGJ-707 is currently in Phase III clinical trials for NSCLC and Phase II for other indications, indicating a robust pipeline for Sanofi's innovative therapies [2]. - The trend of Chinese innovative drug companies entering into licensing agreements with multinational pharmaceutical companies is growing, driven by the increasing recognition of Chinese innovation and the need for multinational firms to address patent cliffs [3][4].

证券代码： 688336 证券简称：三生国健 公告编号：2025-021 三生国健药业（上海）股份有限公司 关于与关联方共同签署许可协议暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ? 交易内容：三生国健药业（上海）股份有限公司（以下简称"本 公司"或"公司"或"三生国健"）及本公司的关联方三生制药和沈 阳三生制药有限责任公司（以下简称"沈阳三生"）共同授予被许可 方辉瑞公司（Pfizer Inc.）（以下简称"辉瑞"）在许可区域（即 除中国大陆以外的其他国家和地区）及领域（即人类和兽医用途的所 有治疗、诊断及预防适应症）的独家开发、生产和商业化许可产品 此外，被许可方保留通过支付额外的付款获得在中国大陆商业化许可 产品的权利。对于被许可方支付给许可方的所有款项将在遵守排他性 许可协议约定的前提下，按照各许可方对许可产品的前期研发投入、 截至《许可协议》签署日各方拥有的有关许可产品的资产权属等合理 因素于各方之间合理分配，具体分配比例为：三生国健 30%，沈阳三 生 70%。 ? 本交易 ...

Core Viewpoint - The biotech sector, particularly companies involved in monoclonal antibody cancer therapies, experienced significant stock price volatility due to competitive developments, particularly the FDA approval of Akeso's cancer drug [1][2]. Group 1: Company Developments - Summit Therapeutics saw its shares drop by 36.1% following the news of Akeso's FDA approval, despite having positive phase 3 trial data for ivonescimab [1][5]. - BioNTech's shares fell by 15.4%, likely influenced by the competitive landscape as Akeso's drug received approval while BioNTech's drugs remain in late-stage trials [1][7]. - Akeso's penpulimab-kcqx received FDA approval for treating nasopharyngeal carcinoma, and ivonescimab was approved in China for PD-L1-positive non-small cell lung cancer [3][4]. Group 2: Competitive Landscape - Akeso's approval of its cancer drugs has created a competitive challenge for Summit, especially since Akeso holds rights to ivonescimab in China [4][5]. - The approval of Akeso's drugs may allow it to explore additional cancer treatments, potentially impacting Summit's market position [6]. - The rapid developments in the bispecific antibody space highlight the intense competition and uncertainty in the biotech industry, affecting investor sentiment towards companies like Summit and BioNTech [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 ALPHAMAB ONCOLOGY 康寧傑瑞生物製藥 （於開曼群島註冊成立的有限公司） （股份代號：9966） 自願公告 JSKN003獲得國家藥監局突破性療法認定 1 關於JSKN003 JSKN003是一種靶向HER2雙表位ADC，其通過糖基定點偶聯技術將拓撲異構酶 I抑制劑連接至抗體KN026（重組人源化抗HER2雙特異性抗體）的N糖基化位點 處。點擊反應偶聯物較馬來醯亞胺－邁克爾反應的偶聯物具有更好的血清穩定 性。雙表位HER2靶向性使JSKN003具有更強的內吞誘導及旁觀者殺傷效應，使 其在HER2表達腫瘤中具有較強的抗腫瘤活性。 關於本公司 本公司是一家中國領先的生物製藥公司，在雙特異性抗體、多功能蛋白質工程及 ADC方面擁有完善的專有技術平台。本公司高度差異化的內部管線由處於不同研 發階段的腫瘤單克隆抗體、雙特異性抗體及ADC組成，包括一種已獲國家藥監局 批准上市及三種處於臨床後期階段的藥 ...